title: Calcium channel modulators and susceptibility to ischaemic ventricular fibrillation: modification of cellular calcium overload.
abstract: The effects of the calcium channel modulators, Bay k 8644, infused i.v. at a rate of 2.5 micrograms/kg/min, and diltiazem, injected i.v. in a dose of 0.5 mg/kg, on the susceptibility to fibrillation induced by ischaemia, were investigated in anaesthetized, open-chest pigs. Ischaemia was produced, under ventricular pacing at constant high rate (180 beats/min), by transient complete occlusion of the left anterior descending coronary artery, near its origin. It was maintained till the triggering of fibrillation. The propensity to fibrillation was judged from the time elapsing between the onset of occlusion and the onset of fibrillation (time to fibrillation). In addition to the surface electrocardiogram, conduction time and monophasic action potential were recorded in the ventricular contractile fibres, as were dP/dtmax in the left ventricle and blood pressure in the carotid artery. At the end of a 10 min infusion, Bay k 8644 lowered to a large extent (about 40%) the time to fibrillation, which returned to its control values within the following 20 min. Conversely, diltiazem increased the time to fibrillation by a factor 4 or 5 at 5 min after its administration. This time to fibrillation remained substantially increased 25 min later. These changes were not associated with alterations in conduction time or monophasic action potential duration in the absence of ischaemia, but with significant alterations in myocardial contractility and blood pressure: in the direction of an increase with Bay k 8644 and of a decrease with diltiazem. These results are in agreement with the enhancement by Bay k 8644 and the prevention by diltiazem of cell calcium overload which is at present recognized as being the essential determinant of the fibrillatory process.
authors.affiliation: Department of Medical Pharmacology, Claude Bernard University, Lyon, France.
authors.forename: Q
authors.initials: Q
authors.lastname: Timour
authors.forename: J P
authors.initials: JP
authors.lastname: Larbre
authors.forename: I
authors.initials: I
authors.lastname: Kioueh
authors.forename: J F
authors.initials: JF
authors.lastname: Aupetit
authors.forename: J
authors.initials: J
authors.lastname: Loufoua-Moundanga
authors.forename: A
authors.initials: A
authors.lastname: Vialle
authors.forename: G
authors.initials: G
authors.lastname: Faucon
mesh_terms: D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000502:physiology*; D015220:Calcium Channels / Q000187:drug effects*; D004110:Diltiazem / Q000494:pharmacology; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D008297:Male; D017202:Myocardial Ischemia / Q000503:physiopathology*; D013552:Swine; D014693:Ventricular Fibrillation / Q000503:physiopathology*
chemical_list: D015220:Calcium Channels; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D004110:Diltiazem; D002118:Calcium